Zymeworks replaces half its C-suite, aims to lay off 25% of total workforce as new CEO takes over
New Zymeworks CEO Kenneth Galbraith is aiming to hit the ground running when his tenure officially begins next month, but he’ll be doing so with a much different looking team.
In a lengthy press release outlining the biotech’s 2022 goals, Galbraith said Zymeworks will be laying off at least 25% of its staff over the course of the year. Half of its C-suite will also be replaced immediately as Galbraith looks to remake the company in his image after Ali Tehrani, Zymeworks’ founder and CEO since 2003, stepped down two weeks ago.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 151,300+ biopharma pros reading Endpoints daily — and it's free.